Salivary Measurement of Deferiprone Concentrations and Correlation with Serum Levels
- 1 February 1997
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 19 (1) , 95-97
- https://doi.org/10.1097/00007691-199702000-00018
Abstract
Deferiprone (L1) is the first clinically available oral iron chelator and it has been proven to be effective for the treatment of transfusional iron overload in thalassemic patients. Because many of these patients have impaired compliance with their medications, effective means of continuous monitoring of compliance are crucial. Saliva drug monitoring has the potential advantage of an easy, noninvasive approach, assuming that it represents serum levels. However, drugs have variable correlations between saliva and serum concentration. We compared serum and saliva levels of L1 at various time points after ingestion of a 75 mg/kg/day dose in nine thalassemic patients. A highly significant correlation between serum-free L1 and saliva levels (r = 0.97, p = 0.0003) was found. Pharmacokinetic profiles were similar using serum and saliva monitoring. We conclude that saliva can be substituted for serum in monitoring L1 levels.Keywords
This publication has 9 references indexed in Scilit:
- Evaluation of Therapeutic Drug Monitoring of Methotrexate in Saliva of Children with Rheumatic DiseasesTherapeutic Drug Monitoring, 1995
- Salivary Excretion of Drugs in Children: Theoretical and Practical Issues in Therapeutic Drug MonitoringDevelopmental Pharmacology and Therapeutics, 1992
- Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemiaClinical Pharmacology & Therapeutics, 1991
- A High-Performance Liquid Chromatographic Method for the Measurement of the Iron Chelator 1,2-Dimethyl-3-hydroxypyridin-4-one in Human PlasmaTherapeutic Drug Monitoring, 1991
- Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patientsThe Lancet, 1990
- Long‐term trial with the oral iron chelator 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one (L1) I. IRON CHELATION AND METABOLIC STUDIESBritish Journal of Haematology, 1990
- Monitoring Theophylline Therapy Using Citric Acid-Stimulated Saliva in Infants and Children With AsthmaPediatrics, 1987
- Correlation between the saliva and free serum concentration of phenobarbital in epileptic childrenEuropean Journal of Pediatrics, 1986
- Visual and Auditory Neurotoxicity in Patients Receiving Subcutaneous Deferoxamine InfusionsNew England Journal of Medicine, 1986